Free Trial
→ Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free KALA Stock Alerts

KALA BIO (KALA) Financials

KALA BIO logo
$0.14 -0.02 (-13.79%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.14 0.00 (-2.02%)
As of 11/13/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for KALA BIO

Annual Income Statements for KALA BIO

This table shows KALA BIO's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 -33 -42 -67 -94 -104 -143 -45 -42 -39 -27
Consolidated Net Income / (Loss)		 -17 -33 -42 -67 -94 -104 -143 -45 -42 -39 -27
Net Income / (Loss) Continuing Operations		 -17 -33 -42 -67 -94 -104 -143 -45 -42 -39 -27
Total Pre-Tax Income 		-17 -33 -42 -67 -94 -104 -143 -45 -42 -39 -27
Total Operating Income		 -16 -33 -40 -65 -88 -96 -130 -82 -40 -41 -39
Total Gross Profit		 0.05 0.00 0.00 0.00 4.07 3.19 7.14 1.33 0.00 0.00 0.00
Total Revenue		 0.05 0.00 0.00 0.00 6.07 6.36 11 3.89 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 2.01 3.17 4.10 2.56 0.00 0.00 0.00
Total Operating Expenses		 16 33 40 65 92 99 137 83 40 41 39
Selling, General & Admin Expense		 4.61 7.64 11 35 65 81 105 65 21 18 24
Research & Development Expense		 11 25 29 29 27 18 38 18 19 22 19
Other Operating Expenses / (Income)		 - - - - - 0.00 -5.81 0.35 0.74 0.55 -4.66
Impairment Charge		 - - - - - - - - - 0.00 1.41
Total Other Income / (Expense), net		 -0.74 -0.50 -2.34 -2.02 -6.12 -8.10 -12 37 -2.54 2.47 12
Interest Expense		 0.60 0.77 1.02 3.70 8.48 8.59 14 9.85 5.81 5.78 -2.52
Interest & Investment Income		 0.00 0.15 0.53 1.69 2.36 0.49 0.10 0.66 2.71 2.06 1.14
Other Income / (Expense), net		 -0.13 0.12 -1.84 - - 0.00 1.31 46 0.57 6.20 8.52
Basic Earnings per Share		 ($14.89) ($28.07) ($3.71) ($2.49) ($2.76) ($1.99) ($108.32) ($29.48) ($17.35) ($10.15) ($3.31)
Weighted Average Basic Shares Outstanding		 1.12M 1.18M 11.38M 26.75M 34.21M 52.38M 1.32M 1.52M 2.43M 3.80M 8.15M
Diluted Earnings per Share		 ($14.89) ($28.07) ($3.71) ($2.49) ($2.76) ($1.99) ($108.32) ($29.48) ($17.35) ($10.15) ($3.31)
Weighted Average Diluted Shares Outstanding		 1.12M 1.18M 11.38M 26.75M 34.21M 52.38M 1.32M 1.52M 2.43M 3.80M 8.15M

Quarterly Income Statements for KALA BIO

This table shows KALA BIO's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -8.63 -12 -9.58 -8.95 -8.18 -11 -11 -7.56 0.69 -1.62 -1.58
Consolidated Net Income / (Loss)		 -8.63 -12 -9.58 -8.95 -8.18 -11 -11 -7.56 0.69 -1.62 -1.58
Net Income / (Loss) Continuing Operations		 -8.63 -12 -9.58 -8.95 -8.18 -11 -11 -7.56 0.69 -1.62 -1.58
Total Pre-Tax Income 		-8.63 -12 -9.58 -8.95 -8.18 -11 -11 -7.56 0.69 -1.62 -1.58
Total Operating Income		 -9.62 -12 -9.61 -9.99 -9.46 -11 -11 -7.24 -10 -1.80 -1.72
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 9.62 12 9.61 9.99 9.46 11 11 7.24 10 1.80 1.72
Selling, General & Admin Expense		 4.62 5.42 4.32 4.40 4.20 4.59 4.64 4.53 9.86 1.74 1.66
Research & Development Expense		 4.72 6.35 5.32 5.17 5.26 6.06 6.23 6.13 0.37 0.06 0.06
Other Operating Expenses / (Income)		 0.51 0.16 -0.03 0.42 - - 0.15 -4.83 - - 0.00
Total Other Income / (Expense), net		 0.99 0.12 0.03 1.04 1.28 -0.63 -0.13 -0.33 11 0.18 0.14
Interest Expense		 1.47 1.46 1.46 1.48 1.39 1.09 1.08 0.96 -5.65 0.00 0.00
Interest & Investment Income		 0.61 0.50 0.50 0.57 0.48 0.46 0.41 0.27 - 0.07 0.14
Other Income / (Expense), net		 1.85 1.08 0.98 1.95 2.20 0.00 0.55 0.37 5.26 0.11 0.00
Basic Earnings per Share		 ($3.55) ($4.20) ($3.16) ($1.93) ($2.15) ($70.49) ($85.64) ($1.07) $0.88 ($0.14) ($21.32)
Weighted Average Basic Shares Outstanding		 2.43M 2.81M 3.03M 4.63M 3.80M 126.92K 130.26K 7.04M 8.15M 11.87M 74.16K
Diluted Earnings per Share		 ($3.55) ($4.20) ($3.16) ($1.93) ($2.15) ($70.49) ($85.64) ($1.07) $0.88 ($0.14) ($21.32)
Weighted Average Diluted Shares Outstanding		 2.43M 2.81M 3.03M 4.63M 3.80M 126.92K 130.26K 7.04M 8.15M 11.87M 74.16K
Weighted Average Basic & Diluted Shares Outstanding		 2.82M 2.82M 4.61M 4.61M 6.45M 6.45M 7.02M 8.21M 0.00 18.59M 19.34M

Annual Cash Flow Statements for KALA BIO

This table details how cash moves in and out of KALA BIO's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -4.86 40 69 68 -85 -8.28 5.12 -24 -20 0.29 -44
Net Cash From Operating Activities		 -15 -27 -34 -54 -93 -91 -108 -79 -28 -29 -32
Net Cash From Continuing Operating Activities		 -15 -27 -34 -54 -93 -91 -108 -79 -28 -29 -32
Net Income / (Loss) Continuing Operations		 -17 -33 -42 -67 -94 -104 -143 -45 -42 -39 -27
Consolidated Net Income / (Loss)		 -17 -33 -42 -67 -94 -104 -143 -45 -42 -39 -27
Depreciation Expense		 0.33 0.30 0.29 0.35 0.84 0.91 0.98 0.54 0.30 0.26 0.32
Amortization Expense		 0.13 0.11 0.47 0.27 0.96 1.05 1.52 1.43 1.25 1.25 -0.67
Non-Cash Adjustments To Reconcile Net Income		 0.79 3.74 5.42 9.61 12 15 42 -37 3.82 9.40 0.86
Changes in Operating Assets and Liabilities, net		 0.34 1.81 1.94 2.38 -12 -3.57 -11 0.49 8.90 -1.78 -5.52
Net Cash From Investing Activities		 -0.25 -0.15 -0.48 -1.58 -1.34 -78 71 63 -0.43 -0.21 -0.02
Net Cash From Continuing Investing Activities		 -0.25 -0.15 -0.48 -1.58 -1.34 -78 71 63 -0.43 -0.21 -0.02
Purchase of Property, Plant & Equipment		 -0.25 -0.15 -0.48 -1.58 -1.34 -1.94 -0.89 -0.31 -0.61 -0.21 -0.02
Net Cash From Financing Activities		 10 67 104 124 8.98 161 43 -7.94 8.51 30 -12
Net Cash From Continuing Financing Activities		 10 67 104 124 8.98 161 43 -7.94 8.51 30 -12
Repayment of Debt		 -0.12 -1.76 -1.11 -22 - 0.00 -78 -40 -10 -5.00 -22
Issuance of Preferred Equity		 7.00 68 - - - - 0.00 31 1.97 8.54 1.80
Issuance of Common Equity		 0.00 0.00 94 71 8.43 161 43 1.34 19 27 9.09
Other Financing Activities, net		 0.10 0.00 0.42 3.26 0.56 -0.03 -0.04 -0.04 -2.04 -0.16 -0.09
Cash Interest Paid		 0.44 0.68 0.86 3.04 7.52 7.53 6.84 5.96 4.62 4.61 2.70

Quarterly Cash Flow Statements for KALA BIO

This table details how cash moves in and out of KALA BIO's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -5.17 -2.42 0.78 -0.05 1.98 -8.96 -10 -11 -14 -5.79 -1.54
Net Cash From Operating Activities		 -7.70 -11 -9.22 -4.73 -4.60 -8.82 -7.73 -11 -4.56 -2.90 -1.54
Net Cash From Continuing Operating Activities		 -7.70 -11 -9.22 -4.73 -4.60 -8.82 -7.73 -11 -4.56 -2.90 -1.54
Net Income / (Loss) Continuing Operations		 -8.63 -12 -9.58 -8.95 -8.18 -8.95 -11 -7.56 0.69 -1.62 -1.58
Consolidated Net Income / (Loss)		 -8.63 -12 -9.58 -8.95 -8.18 -8.95 -11 -7.56 0.69 -1.62 -1.58
Non-Cash Adjustments To Reconcile Net Income		 2.73 2.63 2.04 2.55 2.18 2.42 2.49 -1.28 -2.77 1.28 -0.14
Changes in Operating Assets and Liabilities, net		 -2.18 -2.05 -2.05 1.29 1.03 -2.55 0.69 -2.28 -1.39 -2.56 0.18

Annual Balance Sheets for KALA BIO

This table presents KALA BIO's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 46 117 221 154 222 139 87 56 55 9.49
Total Current Assets		 46 115 177 105 171 124 86 53 53 9.49
Cash & Equivalents		 45 115 171 85 77 92 70 51 51 7.56
Short-Term Investments		 - - - 0.00 76 - - - - 0.00
Prepaid Expenses		 0.15 0.65 2.04 3.82 3.01 6.20 7.85 1.98 1.62 1.93
Plant, Property, & Equipment, net		 0.59 0.79 2.17 2.70 3.17 2.72 0.40 0.75 0.75 0.00
Total Noncurrent Assets		 0.11 0.55 42 46 47 12 0.48 2.33 1.94 0.00
Total Liabilities & Shareholders' Equity		 46 117 221 154 222 139 87 56 55 9.49
Total Liabilities		 16 27 116 125 122 123 68 48 43 2.49
Total Current Liabilities		 5.55 15 17 25 22 37 26 8.35 17 2.49
Accounts Payable		 1.00 1.20 5.45 2.52 1.72 4.90 2.83 0.92 0.63 0.99
Accrued Expenses		 3.99 6.61 11 21 19 21 8.91 6.02 4.98 1.51
Total Noncurrent Liabilities		 10 12 99 100 99 85 42 40 26 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -88 90 105 30 100 17 19 7.50 12 7.00
Total Preferred & Common Equity		 -88 90 105 30 100 17 19 7.50 12 7.00
Preferred Stock		 0.00 0.00 - - - - 0.00 0.00 0.00 0.00
Total Common Equity		 -88 90 105 30 100 17 19 7.50 12 7.00
Common Stock		 4.38 224 306 325 500 559 606 637 680 702
Retained Earnings		 -92 -134 -201 -295 -400 -542 -587 -629 -668 -695

Quarterly Balance Sheets for KALA BIO

This table presents KALA BIO's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 67 61 53 62 54 48 36 25 12 11
Total Current Assets		 66 58 50 59 51 46 34 24 12 11
Cash & Equivalents		 49 56 48 54 49 42 32 21 1.76 0.23
Short-Term Investments		 9.92 - - - - - - - 7.00 7.00
Prepaid Expenses		 1.11 1.84 1.61 4.66 2.08 3.50 1.72 3.18 3.55 3.35
Plant, Property, & Equipment, net		 0.64 0.80 0.71 0.62 0.76 0.70 0.66 0.60 0.00 0.00
Total Noncurrent Assets		 0.33 2.42 2.23 2.14 2.04 1.84 1.73 0.14 0.00 0.00
Total Liabilities & Shareholders' Equity		 67 61 53 62 54 48 36 25 12 11
Total Liabilities		 49 50 46 48 47 43 39 34 1.56 1.54
Total Current Liabilities		 9.85 10 12 19 24 23 16 33 1.56 1.54
Accounts Payable		 0.76 0.79 0.73 0.67 0.71 0.93 0.66 0.92 1.04 1.14
Accrued Expenses		 4.90 6.26 4.81 3.92 4.50 4.04 3.84 2.83 0.51 0.40
Total Noncurrent Liabilities		 39 40 34 29 23 20 23 1.11 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 17 11 6.66 14 6.86 5.71 -3.21 -8.67 11 9.04
Total Preferred & Common Equity		 17 11 6.66 14 6.86 5.71 -3.21 -8.67 11 9.04
Preferred Stock		 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 17 11 6.66 14 6.86 5.71 -3.21 -8.67 11 9.04
Common Stock		 630 632 648 665 667 683 685 687 707 707
Retained Earnings		 -612 -621 -641 -651 -660 -677 -688 -696 -697 -698

Annual Metrics And Ratios for KALA BIO

This table displays calculated financial ratios and metrics derived from KALA BIO's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 24,521,131.00 33,795,656.00 34,543,759.00 56,075,211.00 65,500,275.00 1,518,424.00 2,693,116.00 4,610,139.00 8,209,725.00
DEI Adjusted Shares Outstanding		 0.00 0.00 490,423.00 675,913.00 690,875.00 1,121,504.00 1,310,006.00 1,518,424.00 2,693,116.00 4,610,139.00 8,209,725.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -86.07 -98.74 -136.56 -93.02 -108.86 -29.52 -15.67 -8.35 -3.29
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -100.00% 0.00% 0.00% 0.00% 4.74% 76.67% -65.37% -100.00% 0.00% 0.00%
EBITDA Growth		 0.00% -105.87% -27.44% -56.46% -34.84% -9.07% -34.13% 73.37% -11.48% 11.36% 6.88%
EBIT Growth		 0.00% -102.43% -28.18% -55.14% -36.31% -9.08% -33.98% 72.36% -9.71% 11.03% 11.92%
NOPAT Growth		 0.00% -104.87% -22.06% -62.31% -36.31% -9.08% -35.35% 37.27% 51.46% -3.33% 4.45%
Net Income Growth		 0.00% -98.82% -27.27% -58.11% -41.37% -10.58% -36.69% 68.57% 5.85% 8.74% 29.94%
EPS Growth		 0.00% -88.52% 86.78% 32.88% -10.84% 27.90% -36.69% 72.78% 41.15% 41.50% 67.39%
Operating Cash Flow Growth		 0.00% -81.24% -24.68% -58.72% -71.32% 2.19% -19.34% 27.10% 64.61% -5.21% -8.88%
Free Cash Flow Firm Growth		 0.00% 0.00% -52.78% -63.05% -94.39% 16.98% -10.99% 40.26% 50.89% -28.16% -19.62%
Invested Capital Growth		 0.00% 0.00% -20.16% -24.10% 295.28% 21.20% -68.34% -174.97% -107.32% 8.59% 93.33%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 24.11% 19.95% -3.29% -32.29% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -23.77% 3.94% -10.24% -14.88% 70.98% 9.32% 1.46% 2.64%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -23.76% 3.68% -10.05% -14.70% 69.87% 8.97% 1.44% 6.97%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -23.76% 3.68% -10.05% -15.86% 30.92% 1.57% 0.39% -2.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -26.37% 3.34% 16.30% -47.50% 43.65% 9.08% 1.16% 24.72%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -119.58% 5.80% -17.06% -47.50% 44.45% 4.67% -20.55% 34.97%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 2.19% -21.09% -2.46% -9.29% -1.87% 15.22% 17.78% 9.54% 0.13%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -20.97% 7.35% -4.15% 22.63% 4.32% 9.46% -7.74%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -234.04% 300.18% -0.95% -61.70% 34.70% 16.06% -16.75% 58.44%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 66.94% 50.13% 63.55% 34.22% 0.00% 0.00% 0.00%
EBITDA Margin		 -34,697.78% 0.00% 0.00% 0.00% -1,422.84% -1,481.69% -1,124.91% -865.24% 0.00% 0.00% 0.00%
Operating Margin		 -35,435.56% 0.00% 0.00% 0.00% -1,452.49% -1,512.59% -1,158.76% -2,099.33% 0.00% 0.00% 0.00%
EBIT Margin		 -35,728.89% 0.00% 0.00% 0.00% -1,452.49% -1,512.59% -1,147.10% -915.65% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -37,071.11% 0.00% 0.00% 0.00% -1,553.29% -1,639.85% -1,268.73% -1,151.64% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 103.76% 101.90% 101.18% 103.12% 106.94% 108.41% 110.60% 125.77% 107.94% 110.71% 88.06%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -1,640.94% -394.79% -740.69% -7,718.52% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -1,589.68% -317.43% -629.10% -7,790.67% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 1,500.82% 233.90% 496.50% 7,467.96% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -108.29% -70.17% -68.57% -140.12% -160.89% -244.19% -250.56% -318.75% -388.29% -279.18%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -551.53% -413.96% -636.88% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -47.02% -51.20% -71.43% -31.50% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -50.28% -55.50% -79.00% -39.62% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 310.28% -1.12% -68.57% -140.12% -160.89% -244.19% -250.56% -318.75% -388.29% -279.17%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 37.79% -47.07% -63.57% -317.75% -104.33% -848.64% -236.23% -562.35% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -23 -28 -45 -62 -67 -91 -57 -28 -29 -27
NOPAT Margin		 -24,804.89% 0.00% 0.00% 0.00% -1,016.74% -1,058.81% -811.13% -1,469.53% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -57.33% -21.67% -20.52% -51.27% -77.36% -111.59% 72.15% -71.96% -52.46% 3.06%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -66.59% -67.08% -391.83%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 33.06% 49.87% 36.45% 65.78% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 10,242.22% 0.00% 0.00% 0.00% 1,070.38% 1,274.25% 934.71% 1,670.99% 0.00% 0.00% 0.00%
R&D to Revenue		 25,293.33% 0.00% 0.00% 0.00% 449.05% 288.46% 339.25% 453.57% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 35,535.56% 0.00% 0.00% 0.00% 1,519.43% 1,562.72% 1,222.31% 2,133.56% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -16 -33 -42 -65 -88 -96 -129 -36 -39 -35 -31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -32 -41 -64 -86 -94 -126 -34 -38 -33 -31
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 5.06 1.57 4.29 3.80 4.72 3.05 2.51 2.59 0.65
Price to Tangible Book Value (P/TBV)		 0.00 0.00 5.06 1.57 4.29 3.80 4.72 3.05 2.51 2.59 0.65
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 20.99 59.76 7.05 14.88 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 7.34 15.99 11.46 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 18.64 46.98 6.03 8.87 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.32 0.21 0.67 2.40 0.72 4.92 2.48 4.56 2.47 0.00
Long-Term Debt to Equity		 0.00 0.30 0.13 0.67 2.40 0.72 4.70 2.00 4.56 1.63 0.00
Financial Leverage		 0.00 -1.17 -1.10 -1.07 -0.94 -0.74 -0.79 -0.96 -1.52 -1.89 -1.46
Leverage Ratio		 0.00 1.51 1.35 1.73 2.79 2.90 3.09 6.32 5.39 5.62 3.36
Compound Leverage Factor		 0.00 1.54 1.37 1.79 2.98 3.14 3.42 7.95 5.82 6.22 2.96
Debt to Total Capital		 0.00% 23.97% 17.22% 40.08% 70.57% 41.94% 83.12% 71.28% 82.00% 71.17% 0.00%
Short-Term Debt to Total Capital		 0.00% 1.38% 6.15% 0.00% 0.00% 0.00% 3.83% 13.85% 0.00% 24.17% 0.00%
Long-Term Debt to Total Capital		 0.00% 22.59% 11.07% 40.08% 70.57% 41.94% 79.29% 57.43% 82.00% 47.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
Noncontrolling Interests to Total Capital		 0.00% 293.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -217.86% 82.78% 59.92% 29.43% 58.06% 16.88% 28.72% 18.00% 28.83% 99.99%
Debt to EBITDA		 0.00 -0.30 -0.46 -1.10 -0.82 -0.77 -0.65 -1.40 -0.91 -0.91 0.00
Net Debt to EBITDA		 0.00 1.11 2.34 1.57 0.17 0.86 0.09 0.70 0.45 0.62 0.00
Long-Term Debt to EBITDA		 0.00 -0.28 -0.29 -1.10 -0.82 -0.77 -0.62 -1.13 -0.91 -0.60 0.00
Debt to NOPAT		 0.00 -0.42 -0.67 -1.55 -1.15 -1.07 -0.91 -0.82 -1.23 -1.06 0.00
Net Debt to NOPAT		 0.00 1.57 3.44 2.22 0.23 1.21 0.13 0.41 0.60 0.72 0.00
Long-Term Debt to NOPAT		 0.00 -0.40 -0.43 -1.55 -1.15 -1.07 -0.87 -0.66 -1.23 -0.70 0.00
Altman Z-Score		 0.00 0.00 8.36 -0.52 -3.29 -1.25 -7.28 -9.43 -16.87 -17.70 -111.19
Noncontrolling Interest Sharing Ratio		 0.00% 386.53% 98.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 8.23 7.75 10.41 4.26 7.71 3.32 3.35 6.33 3.11 3.81
Quick Ratio		 0.00 8.20 7.70 10.05 3.92 7.34 2.87 2.74 6.10 3.02 3.03
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -18 -27 -44 -85 -71 -78 -47 -23 -29 -35
Operating Cash Flow to CapEx		 -5,987.70% -17,874.51% -7,103.75% -3,429.72% -6,945.32% -4,670.13% -13,631.61% -39,652.26% -4,960.39% -14,125.96% -213,273.33%
Free Cash Flow to Firm to Interest Expense		 0.00 -22.91 -26.34 -11.82 -10.03 -8.22 -5.69 -4.76 -3.96 -5.10 0.00
Operating Cash Flow to Interest Expense		 -24.98 -35.66 -33.46 -14.61 -10.93 -10.56 -7.86 -8.01 -4.80 -5.08 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -25.40 -35.86 -33.93 -15.04 -11.09 -10.79 -7.92 -8.03 -4.90 -5.12 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.03 0.03 0.06 0.03 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.60 0.90 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.46 0.64 0.59 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 2.50 2.17 3.82 2.49 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.50 1.50 1.24 0.66 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 607.20 405.09 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 794.62 568.09 617.75 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 723.82 243.99 295.02 551.14 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 70.80 931.30 727.82 -551.14 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -5.30 -6.37 -7.90 15 19 5.92 -4.44 -9.20 -8.41 -0.56
Invested Capital Turnover		 0.00 0.00 0.00 0.00 1.61 0.37 0.91 5.25 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -5.30 -1.07 -1.53 23 3.27 -13 -10 -4.76 0.79 7.85
Enterprise Value (EV)		 0.00 0.00 357 65 113 299 68 35 2.15 11 -2.99
Market Capitalization		 0.00 0.00 453 165 127 380 79 58 19 32 4.56
Book Value per Share		 $0.00 ($74.28) $3.66 $3.11 $0.86 $1.78 $0.26 $12.50 $2.79 $2.68 $0.85
Tangible Book Value per Share		 $0.00 ($74.28) $3.66 $3.11 $0.86 $1.78 $0.26 $12.50 $2.79 $2.68 $0.85
Total Capital		 0.00 40 108 175 101 172 100 66 42 43 7.00
Total Debt		 0.00 9.65 19 70 71 72 83 47 34 30 0.00
Total Long-Term Debt		 0.00 9.10 12 70 71 72 79 38 34 20 0.00
Net Debt		 0.00 -36 -96 -101 -14 -81 -11 -23 -17 -21 -7.56
Capital Expenditures (CapEx)		 0.25 0.15 0.48 1.58 1.34 1.94 0.79 0.20 0.56 0.21 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -4.84 -7.56 -11 -4.74 -4.39 -3.42 -1.09 -6.37 -5.00 -0.56
Debt-free Net Working Capital (DFNWC)		 0.00 41 107 160 81 149 91 69 45 46 7.00
Net Working Capital (NWC)		 0.00 40 100 160 81 149 87 60 45 36 7.00
Net Nonoperating Expense (NNE)		 5.52 10 14 21 33 37 51 -12 14 9.82 -0.43
Net Nonoperating Obligations (NNO)		 0.00 -36 -96 -113 -14 -81 -11 -23 -17 -21 -7.56
Total Depreciation and Amortization (D&A)		 0.46 0.40 0.75 0.63 1.80 1.97 2.49 1.96 1.56 1.51 -0.35
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -78.02% -68.94% -30.40% -28.06% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 1,328.78% 2,344.45% 807.48% 1,783.22% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 1,328.78% 2,344.45% 773.52% 1,548.23% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($744.50) ($1,403.50) ($305.50) ($124.50) ($138.00) ($99.50) ($109.50) ($29.48) ($17.35) ($10.15) ($3.31)
Adjusted Weighted Average Basic Shares Outstanding		 22.41K 23.63K 491.12K 677.66K 736.08K 1.23M 1.30M 1.52M 2.43M 3.80M 8.15M
Adjusted Diluted Earnings per Share		 ($744.50) ($1,403.50) ($305.50) ($124.50) ($138.00) ($99.50) ($109.50) ($29.48) ($17.35) ($10.15) ($3.31)
Adjusted Weighted Average Diluted Shares Outstanding		 22.41K 23.63K 491.12K 677.66K 736.08K 1.23M 1.30M 1.52M 2.43M 3.80M 8.15M
Adjusted Basic & Diluted Earnings per Share		 ($744.50) ($1,403.50) ($305.50) ($124.50) ($138.00) ($99.50) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 22.41K 23.63K 138.07K 535.08K 684.20K 1.05M 1.45M 2.03M 2.82M 6.45M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -23 -28 -45 -62 -67 -91 -57 -28 -29 -26
Normalized NOPAT Margin		 -24,804.89% 0.00% 0.00% 0.00% -1,016.74% -1,058.81% -811.13% -1,469.53% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -37,071.11% 0.00% 0.00% 0.00% -1,553.29% -1,639.85% -1,268.73% -1,151.64% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -26.62 -42.43 -40.94 -17.47 -10.40 -11.20 -9.36 -3.62 -6.72 -6.01 0.00
NOPAT to Interest Expense		 -18.48 -29.82 -27.39 -12.23 -7.28 -7.84 -6.62 -5.81 -4.78 -4.96 0.00
EBIT Less CapEx to Interest Expense		 -27.04 -42.63 -41.41 -17.90 -10.56 -11.43 -9.42 -3.64 -6.82 -6.05 0.00
NOPAT Less CapEx to Interest Expense		 -18.90 -30.01 -27.86 -12.66 -7.44 -8.07 -6.68 -5.83 -4.87 -5.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -9.03% -0.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for KALA BIO

This table displays calculated financial ratios and metrics derived from KALA BIO's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 2,693,116.00 2,816,454.00 2,816,454.00 4,607,569.00 4,610,139.00 6,452,398.00 6,452,398.00 7,021,040.00 8,209,725.00 8,209,725.00 18,589,832.00
DEI Adjusted Shares Outstanding		 2,693,116.00 2,816,454.00 2,816,454.00 4,607,569.00 4,610,139.00 6,452,398.00 6,452,398.00 7,021,040.00 8,209,725.00 164,195.00 18,589,832.00
DEI Earnings Per Adjusted Shares Outstanding		 -3.20 -4.19 -3.40 -1.94 -1.77 -1.39 -1.73 -1.08 0.08 -9.87 -0.09
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 34.31% 20.92% 11.66% -1.22% 6.69% 23.03% -24.15% 13.45% 12.17% 83.73% 83.20%
EBIT Growth		 33.14% 20.50% 11.25% -1.12% 6.54% 23.37% -21.52% 14.56% 31.61% 84.11% 83.58%
NOPAT Growth		 6.17% -2.12% -0.06% -13.99% 1.66% 10.58% -14.82% 27.52% -54.43% 83.11% 84.39%
Net Income Growth		 32.83% 18.32% 8.01% -2.83% 5.24% 24.22% -16.45% 15.49% 108.39% 85.65% 85.83%
EPS Growth		 57.99% 0.00% 27.52% 43.40% 39.44% 66.43% 45.89% 44.56% 140.93% 85.65% 75.11%
Operating Cash Flow Growth		 43.97% -11.98% -21.33% -60.06% 40.25% 18.63% 16.07% -130.20% 0.91% 67.19% 80.15%
Free Cash Flow Firm Growth		 -161.91% -225.84% -209.29% -446.39% -276.15% -31.61% 11.36% -1.60% -143.88% 27.47% -1.64%
Invested Capital Growth		 -107.32% -5.88% 30.23% 34.28% 8.59% 40.86% 7.33% 81.26% 93.33% 146.16% 134.58%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 2.35% -41.84% 21.27% 7.18% 9.98% -17.00% -26.98% 35.29% 8.65% 72.00% -1.53%
EBIT Q/Q Growth		 2.31% -39.73% 20.55% 6.76% 9.71% -14.57% -25.99% 34.44% 27.73% 65.87% -1.53%
NOPAT Q/Q Growth		 -9.78% -24.04% 19.50% -3.99% 5.30% -12.79% -3.36% 34.36% -101.78% 87.66% 4.50%
Net Income Q/Q Growth		 0.88% -36.86% 18.87% 6.57% 8.66% -9.44% -24.68% 32.19% 109.07% -336.30% 2.47%
EPS Q/Q Growth		 -4.11% -18.31% 24.76% 38.92% -11.40% 34.42% -21.28% 37.43% 182.24% -336.30% -15,128.57%
Operating Cash Flow Q/Q Growth		 -160.70% -40.90% 15.02% 48.72% 2.69% -91.91% 12.35% -40.64% 58.11% 36.46% 46.98%
Free Cash Flow Firm Q/Q Growth		 -0.15% -303.27% -15.50% -17.13% 31.06% -41.10% 22.21% -34.26% -65.50% 58.04% -9.01%
Invested Capital Q/Q Growth		 16.06% 20.50% 22.58% -27.21% -16.75% 48.57% -21.31% 74.28% 58.44% 455.97% -9.11%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 111.04% 108.76% 111.06% 111.29% 112.59% 107.55% 106.43% 110.09% -13.81% 95.63% 91.87%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -318.75% -262.61% -248.11% -430.96% -388.29% -576.46% -708.34% 3,969.10% -279.18% -210.14% -264.82%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,378.51% -1,198.56%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -318.75% -262.61% -248.11% -430.96% -388.29% -576.46% -708.34% 3,969.10% -279.17% -210.13% -264.82%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -593.77% 0.00% 0.00% 0.00% -624.58% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.73 -8.35 -6.72 -6.99 -6.62 -7.47 -7.72 -5.07 -10 -1.26 -1.20
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -9.44% -15.58% -12.69% -10.81% -8.30% -12.32% -32.07% -74.00% 77.11% -3.83% -8.12%
Return On Investment Capital (ROIC_SIMPLE)		 -16.15% -20.29% -13.85% -16.65% -15.48% -19.71% -28.92% -25.66% -146.15% -11.72% -13.32%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -7.77 -11 -8.63 -8.04 -7.26 -8.32 -10 -6.87 -4.97 -1.70 -1.72
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.39 -10 -8.25 -7.66 -6.89 -8.07 -10 -6.63 -6.05 -1.70 -1.72
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.51 3.37 1.46 3.83 2.59 6.48 0.00 0.00 0.65 0.13 3.56
Price to Tangible Book Value (P/TBV)		 2.51 3.37 1.46 3.83 2.59 6.48 0.00 0.00 0.65 0.13 3.56
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.74
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 4.56 5.18 2.54 5.12 2.47 5.64 -9.33 -3.28 0.00 0.00 0.00
Long-Term Debt to Equity		 4.56 4.28 1.66 2.50 1.63 2.65 -5.86 0.00 0.00 0.00 0.00
Financial Leverage		 -1.52 -1.47 -1.44 -2.00 -1.89 -1.94 -2.04 3.74 -1.46 -1.14 -1.59
Leverage Ratio		 5.39 4.16 4.10 6.37 5.62 8.19 9.29 -43.80 3.36 3.68 7.99
Compound Leverage Factor		 5.99 4.52 4.56 7.09 6.32 8.81 9.89 -48.22 -0.46 3.52 7.34
Debt to Total Capital		 82.00% 83.82% 71.74% 83.67% 71.17% 84.94% 112.01% 143.88% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 14.56% 24.69% 42.80% 24.17% 45.04% 41.63% 143.88% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 82.00% 69.26% 47.04% 40.86% 47.00% 39.90% 70.38% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 18.00% 16.18% 28.26% 16.33% 28.83% 15.06% -12.01% -43.88% 99.99% 99.99% 100.00%
Debt to EBITDA		 -0.91 -0.99 -1.03 -1.04 -0.91 -1.04 -0.91 -0.89 0.00 0.00 0.00
Net Debt to EBITDA		 0.45 0.40 0.58 0.42 0.62 0.33 0.06 -0.23 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.91 -0.82 -0.68 -0.51 -0.60 -0.49 -0.57 0.00 0.00 0.00 0.00
Debt to NOPAT		 -1.23 -1.24 -1.25 -1.22 -1.06 -1.16 -1.04 -1.06 0.00 0.00 0.00
Net Debt to NOPAT		 0.60 0.50 0.69 0.49 0.72 0.36 0.07 -0.27 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -1.23 -1.02 -0.82 -0.60 -0.70 -0.54 -0.65 0.00 0.00 0.00 0.00
Altman Z-Score		 -15.02 -16.45 -14.23 -16.63 -16.07 -19.12 -26.62 -40.03 -102.26 -78.02 -79.32
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.33 4.22 3.07 2.15 3.11 1.99 2.10 0.75 3.81 7.91 6.88
Quick Ratio		 6.10 4.08 2.82 2.06 3.02 1.84 1.99 0.65 3.03 5.63 4.70
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.97 -7.95 -9.18 -11 -7.41 -10 -8.13 -11 -18 -7.58 -8.27
Operating Cash Flow to CapEx		 -109,942.86% -83,415.38% -25,597.22% -5,250.00% -6,663.77% 0.00% -48,337.50% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -1.34 -5.46 -6.29 -7.27 -5.32 -9.59 -7.53 -11.34 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -5.24 -7.45 -6.32 -3.20 -3.30 -8.09 -7.15 -11.29 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -5.25 -7.46 -6.35 -3.26 -3.35 -8.09 -7.17 -11.29 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -9.20 -7.32 -5.66 -7.20 -8.41 -4.33 -5.25 -1.35 -0.56 2.00 1.82
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -4.76 -0.41 2.45 3.76 0.79 2.99 0.42 5.85 7.85 6.32 7.06
Enterprise Value (EV)		 2.15 8.47 0.59 12 11 27 29 18 -2.99 -7.34 25
Market Capitalization		 19 22 20 26 32 37 31 11 4.56 1.42 32
Book Value per Share		 $2.79 $2.37 $4.87 $1.49 $2.68 $1.24 ($0.50) ($1.23) $0.85 $1.31 $0.49
Tangible Book Value per Share		 $2.79 $2.37 $4.87 $1.49 $2.68 $1.24 ($0.50) ($1.23) $0.85 $1.31 $0.49
Total Capital		 42 41 49 42 43 38 27 20 7.00 11 9.04
Total Debt		 34 35 35 35 30 32 30 28 0.00 0.00 0.00
Total Long-Term Debt		 34 29 23 17 20 15 19 0.00 0.00 0.00 0.00
Net Debt		 -17 -14 -19 -14 -21 -10 -2.04 7.32 -7.56 -8.76 -7.23
Capital Expenditures (CapEx)		 0.01 0.01 0.04 0.09 0.07 0.00 0.02 -0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.37 -4.28 -2.55 -3.81 -5.00 -2.41 -3.18 -0.99 -0.56 2.00 1.82
Debt-free Net Working Capital (DFNWC)		 45 44 52 45 46 40 29 20 7.00 11 9.04
Net Working Capital (NWC)		 45 38 40 27 36 23 18 -8.30 7.00 11 9.04
Net Nonoperating Expense (NNE)		 1.89 3.46 2.86 1.96 1.55 1.48 3.44 2.50 -11 0.36 0.38
Net Nonoperating Obligations (NNO)		 -17 -14 -19 -14 -21 -10 -2.04 7.32 -7.56 -8.76 -7.23
Total Depreciation and Amortization (D&A)		 0.38 0.38 0.38 0.39 0.37 0.25 0.24 0.24 -1.09 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.55) ($4.20) ($3.16) ($1.93) ($2.15) ($1.41) ($1.71) ($1.07) $0.88 ($0.14) ($21.32)
Adjusted Weighted Average Basic Shares Outstanding		 2.43M 2.81M 3.03M 4.63M 3.80M 6.35M 6.51M 7.04M 8.15M 11.87M 74.16K
Adjusted Diluted Earnings per Share		 ($3.55) $0.00 ($3.16) ($1.93) ($2.15) ($1.41) ($1.71) ($1.07) $0.88 ($0.14) ($21.32)
Adjusted Weighted Average Diluted Shares Outstanding		 2.43M 2.81M 3.03M 4.63M 3.80M 6.35M 6.51M 7.04M 8.15M 11.87M 74.16K
Adjusted Basic & Diluted Earnings per Share		 ($3.55) $0.00 $0.00 $0.00 ($2.15) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.82M 2.82M 4.61M 4.61M 6.45M 6.45M 7.02M 8.21M 0.00 18.59M 19.34M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.73 -8.35 -6.72 -6.99 -6.62 -7.47 -7.72 -4.08 -7.16 -1.26 -1.20
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -5.29 -7.46 -5.92 -5.44 -5.22 -7.63 -9.70 -7.14 0.00 0.00 0.00
NOPAT to Interest Expense		 -4.59 -5.74 -4.61 -4.73 -4.76 -6.85 -7.14 -5.26 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -5.30 -7.47 -5.94 -5.50 -5.27 -7.63 -9.71 -7.13 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -4.59 -5.75 -4.64 -4.79 -4.81 -6.85 -7.16 -5.26 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

KALA BIO’s Q2 2026 statements show sharply lower expenses and operating cash burn, alongside a much smaller debt burden. However, the company still reported no revenue, and its cash balance has fallen substantially. The improvement in losses appears tied mainly to reduced spending rather than revenue growth.

  • Operating expenses fell substantially. Q2 2026 expenses were $1.72 million, down from $1.80 million in Q1 2026 and $11.03 million in Q2 2025. Research and development expense was only $59,000, compared with $6.23 million in Q2 2025.
  • Quarterly operating cash burn eased. Cash used in operations was $1.54 million in Q2 2026, versus $2.90 million in Q1 2026 and $7.73 million in Q2 2025.
  • Debt and liabilities are far lower than in 2025. KALA reported no debt in Q2 2026, while total liabilities were $1.54 million. In Q3 2025, short-term debt alone was $28.41 million and total liabilities were $33.69 million.
  • Current assets exceed current liabilities. The company reported $10.58 million in current assets and $1.54 million in current liabilities at quarter-end, including $7 million in short-term investments.
  • The Q2 loss narrowed significantly, but was still a loss. Net loss was $1.58 million, compared with $1.62 million in Q1 2026 and $11.16 million in Q2 2025. The lower loss coincided with a steep decline in operating spending.
  • Q4 2025’s reported profit does not indicate operating profitability. KALA reported net income of $686,000 that quarter despite a $10.23 million operating loss; $10.91 million in net other income more than offset the operating loss.
  • Revenue remains absent in the supplied quarters that report it. KALA recorded no revenue in Q2 2026 or the provided comparable quarters, leaving it dependent on cash and investments to fund operations.
  • Cash has dwindled over the longer term. Cash and equivalents fell from $56.06 million in Q3 2023 to $229,000 in Q2 2026. Short-term investments provide additional liquidity, but cash plus investments were $7.23 million at the latest quarter-end, down from $8.76 million in Q1 2026.
  • R&D spending is now minimal. The reduction may help conserve cash, but quarterly R&D expense of $59,000—down from several million dollars in 2024 and 2025—could limit investment in the company’s development programs.
11/15/26 04:44 AM ETAI Generated. May Contain Errors.

KALA BIO Financials - Frequently Asked Questions

According to the most recent income statement we have on file, KALA BIO's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

The last 5 years of KALA BIO's net income performance:
  • 2021: -$142.61 million
  • 2022: -$44.82 million
  • 2023: -$42.20 million
  • 2024: -$38.51 million
  • 2025: -$26.98 million
Find out what analysts predict for KALA BIO in the coming months.

KALA BIO's total operating income in 2025 was -$39.16 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $39.16 million

Over the last 10 years, KALA BIO's total revenue changed from $45 thousand in 2015 to $0.00 in 2025, a change of -100.0%.

In the past 12 quarters, KALA BIO's cash and equivalents has ranged from $229 thousand in Q2 2026 to $56.06 million in Q3 2023, and is currently $229 thousand as of their latest financial filing in Q2 2026.

KALA BIO had total debt of $0.00 at the end of 2025, a 100.0% decrease from 2024, and none in 2015.

Over the last 10 years, KALA BIO's book value per share changed from 0.00 in 2015 to 0.85 in 2025, a change of 85.2%.


Related Companies

Financial statements for NASDAQ:KALA last updated on 8/19/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
SHOCKING! Prediction caught on camera
Newly released footage shows James Altucher pulling a document out of a briefcase on camera. It is a document ...
Paradigm Press | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel